Shetty Paulina, Youngberg Wes
American College of Lifestyle Medicine, Chesterfield, Missouri (PS).
Loma Linda University Schools of Medicine and Public Health, Youngberg Lifestyle Medicine Clinic, Temecula, California (WY).
Am J Lifestyle Med. 2018 May 11;12(5):391-395. doi: 10.1177/1559827618766468. eCollection 2018 Sep-Oct.
Alzheimer's disease (AD) is the most common form of dementia and currently affects over 5 million Americans and 30 million individuals worldwide. Unfortunately, the current approach to treating AD provides nothing more than a marginal, unsustained, symptomatic effect, with little or no effect on disease progression itself. To attain effective improvements in AD, one must determine risk factors, address the underlying causes, and focus on a combination of functional and lifestyle medicine strategies that provide a comprehensive, programmatic, and network-based approach that is sufficient to achieve epigenetic transformation and neurologic healing through its multiple and necessary synergistic components. Rather than normalizing metabolic parameters, the focus is on optimization of each metabolic parameter. Papers published by research neurologist, Dr Dale Bredesen have documented that symptoms of mild cognitive impairment and early AD may often be reversed within 6 months after initiating a comprehensive, functional and lifestyle medicine-focused program. The purpose of this article are as follows: 1. Shed light on a promising clinical protocol that focuses on a comprehensive functional and lifestyle medicine approach to treating mild cognitive decline and Alzheimer's disease; 2. Identify the Bredesen Protocol testing, diagnostic and treatment guidelines; 3. Review several case studies and discuss the promising results of the program. Although published case studies such as those reported here are relatively few, clinicians applying these comprehensive strategies have reason to expect improvement in their patients. Lifestyle medicine can be a source of greatly needed hope for those suffering with cognitive decline.
阿尔茨海默病(AD)是最常见的痴呆形式,目前影响着超过500万美国人以及全球3000万人。不幸的是,目前治疗AD的方法仅仅只能带来微不足道、难以持续的症状缓解效果,对疾病本身的进展几乎没有影响。为了在AD治疗上取得有效的进展,必须确定风险因素,解决潜在病因,并专注于功能医学和生活方式医学策略的结合,提供一种全面、系统且基于网络的方法,通过其多个必要的协同组成部分足以实现表观遗传转化和神经修复。重点不在于使代谢参数正常化,而是优化每个代谢参数。研究神经学家戴尔·布雷德森博士发表的论文记录了,在启动一个以功能医学和生活方式医学为重点的综合项目后的6个月内,轻度认知障碍和早期AD的症状往往可以得到逆转。本文的目的如下:1. 阐明一种有前景的临床方案,该方案专注于以功能医学和生活方式医学的综合方法治疗轻度认知衰退和阿尔茨海默病;2. 确定布雷德森方案的测试、诊断和治疗指南;3. 回顾几个案例研究并讨论该项目的有前景的结果。尽管像本文所报道的这类已发表的案例研究相对较少,但应用这些综合策略的临床医生有理由期望他们的患者病情得到改善。生活方式医学对于那些患有认知衰退的人来说可能是极需的希望之源。